Active MMP-8 as a Biomarker of Peri-implant Health or Disease

Diagnostic Accuracy of Active MMP-8 Point-of-Care Test in Peri-Implantitis

AIM

 This study aimed to evaluate the diagnostic sensitivity and specificity of the active matrix metalloproteinase-8 (aMMP-8) quantitative chairside point-of-care (PoC) lateral flow immunotest for peri-implant diseases, and it sought to correlate aMMP-8 levels with clinical parameters to determine its effectiveness as a biomarker for peri-implantitis.

MATERIALS AND METHODS

 A cross-sectional study was conducted at the Department of Periodontology and Implant Biology, Aristotle University of Thessaloniki, Greece. Participants included systemically healthy individuals with at least one implant loaded for more than 1 year, who had not received periodontal treatment or antibiotics in the preceding 6 months. Exclusion criteria included diabetes and immune-compromising conditions. Peri-implant sulcular fluid (PISF) samples were collected from the mesiobuccal or distobuccal site of the implant. The quantitative chairside PoC lateral flow immunotest for peri-implant diseases (ImplantSafe test) and ORALyzer digital reader were used to analyze PISF, with results expressed in ng/mL. Clinical parameters such as bleeding on probing (BOP), probing depth (PD), recession (REC), and clinical attachment level (CAL) were measured at six sites per implant using a 15-mm scale periodontal probe.

RESULTS

 No significant differences were found in age, gender distribution, or smoking status between the healthy/mucositis and peri-implantitis groups. The peri-implantitis group showed significantly higher mean percentages of BOP (57.58 ± 31.73 vs. 18.79 ± 24.17), PD (4.59 ± 1.22 mm vs. 2.94 ± 0.78 mm), and CAL (5.21 ± 1.72 mm vs. 3.05 ± 0.81 mm). aMMP-8 levels were also significantly higher in the peri-implantitis group (53.39 ± 49.70 vs. 22.03 ± 32.87). The diagnostic test demonstrated a sensitivity of 81.25% and specificity of 74.07%, with an area under the curve of 79.6%, indicating overall good accuracy in distinguishing between positive and negative conditions.

CONCLUSION

 The aMMP-8 is a promising biomarker for peri-implantitis, showing elevated levels in affected patients. The aMMP-8 chairside test demonstrates high diagnostic sensitivity and specificity, supporting its use in early detection and monitoring of peri-implant diseases. Further research is needed to establish standardized protocols for its clinical application and to explore its long-term predictive value in implant care.

Comparison of clinical parameters of peri-implantitis and parameters related to tissue macrophage sensitization on TiO2

OBJECTIVE

Dental implants show impressive survival and like rates, but peri-implantitis is a frequent inflammatory disease which affects the implant-surrounding tissues. While biofilms on the implant surface is considered its etiologic reason, several risk factors determine the pace of progression of peri-implant bone loss. Some risk factors are generally accepted while others are still unconfirmed and a matter of ongoing discussion. Among the latter, tissue macrophage sensitization on TiO2 has gained scientific interest in recent years. The aim of the present case-control study was to test for potential associations between clinically manifest peri-implantitis and MS related parameters.

MATERIALS AND METHODS

In patients with implants affected by peri-implantitis in the test group and healthy implants in the control group clinical parameters (peri-implant pocket depths (PPD) and bleeding on probing (BOP) were measured. Samples of aMMP-8 were taken from the entrance of the peri-implant sulcus and bacterial samples were collected from the sulcus. Blood samples were obtained from the basilic vein to assess MA-related laboratory parameters. Potential correlations between clinical and laboratory parameters were tested by multiple regression (p < 0.05).

RESULTS

No statistically significant correlations were found between clinical or bacteriological findings and laboratory parameters were found.

CONCLUSIONS

Based on the findings of this study elevated MA-related laboratory parameters do not appear to be linked to peri-implantitis.

CLINICAL RELEVANCE

Sensitization on TiO2 is not associated with clinical symptoms of peri-implantitis.

Clinical parameters and inflammatory biomarkers among patients with multibracket appliances: a prospective clinical trial

BACKGROUND

Aim of the presented study was to investigate changes in clinical parameters and active matrix metalloproteinase-8 (aMMP-8) levels in gingival crevicular fluid of patients before and during treatment with multibrackets appliances.

METHODS

Fifty-five adolescents scheduled for the treatment were included. Clinical parameters and subgingival samples were obtained at six time points: 1 week before appliance insertion (T0), 3 (T1), 6 (T2) weeks, 3 (T3), 6 (T4) months, and 1 year (T5) after that. Gingival index and plaque index were assessed to evaluated changes on the clinical status. Subgingival samples were collected to analyze changes in aMMP-8.

RESULTS

Scores for gingival and plaque index increased after bracket insertion. The gingival index increased from T2 (p < 0.05) until T5 (p < 0.0001). Plaque index also increased, reaching its maximum peak at T3 (p < 0.05). Moreover, an increase of aMMP-8 levels (p < 0.05) was noted. There was no significant between upper and lower jaws.

CONCLUSIONS

Treatment with multibracket appliances in adolescents favors dental plaque accumulation and may transitionally increase gingival and plaque index and aMMP-8 levels leading to gingival inflammation, even 1 year after therapy began.

TRIAL REGISTRATION

This study was approved by the Ethics Committee of the dental medical association Rheiland-Pfalz, Germany (process no. 837.340.12 (8441-F)), and followed the guidelines of Good Clinical Practices.

Peri-implant diseases diagnosis, prognosis and dental implant monitoring: a narrative review of novel strategies and clinical impact

BACKGROUND

The diagnosis of peri-implantar and periodontal relies mainly on a set of clinical measures and the evaluation of radiographic images. However, these clinical settings alone are not sufficient to determine, much less predict, periimplant bone loss or future implant failure. Early diagnosis of periimplant diseases and its rate of progress may be possible through biomarkers assessment. Once identified, biomarkers of peri-implant and periodontal tissue destruction may alert the clinicians before clinical signs show up. Therefore, it is important to consider developing chair-side diagnostic tests with specificity for a particular biomarker, indicating the current activity of the disease.

METHODS

A search strategy was created at Pubmed and Web of Science to answer the question: "How the molecular point-of-care tests currently available can help in the early detection of peri-implant diseases and throws light on improvements in point of care diagnostics devices?"

RESULTS

The PerioSafe® PRO DRS (dentognostics GmbH, Jena) and ImplantSafe® DR (dentognostics GmbH, Jena ORALyzer® test kits, already used clinically, can be a helpful adjunct tool in enhancing the diagnosis and prognosis of periodontal/peri-implantar diseases. With the advances of sensor technology, the biosensors can perform daily monitoring of dental implants or periodontal diseases, making contributions to personal healthcare and improve the current status quo of health management and human health.

CONCLUSIONS

Based on the findings, more emphasis is given to the role of biomarkers in diagnosing and monitoring periodontal and peri-implant diseases. By combining these strategies with traditional protocols, professionals could increase the accuracy of early detection of peri-implant and periodontal diseases, predicting disease progression, and monitoring of treatment outcomes.